CSULA-COH Cancer Collaborative

Slides:



Advertisements
Similar presentations
1Kitasato-Harvard Symposium 10/03/2002 New Monoclonal Antibody Approved for Advanced Breast Cancer Shin-ichi Nihira, Ph.D. Dept. Clinical Research 3 Chugai.
Advertisements

2. Cannabinoids are provided in vials containing the cannabinoids as a resin diluted in ethanol. These vials are stored at -20ºC. 3. In order to prepare.
rhBMP-2: origin, biology and preclinical safety
Walter Piper Dr. Andrew Buermeyer Department of Environmental and Molecular Toxicology Oregon State University 2009 HHMI Undergraduate Research Program.
Can Expression of VACM-1 Enhance Effects of Thalidomide on Endothelial Cell Growth? Drake Harper Zeeland East High School John Pelton Maria Burnatowska-Hledin.
POSTER TEMPLATE BY: Developing Novel Supported Membrane Interfaces for SPR Study of Transmembrane Proteins Heather Ferguson*,
KRAS testing in colorectal cancer: an overview. 2 What is KRAS? KRAS is a gene that encodes one of the proteins in the epidermal growth factor receptor.
Monoclonal antibodies Hybridoma Technique. Monoclonal antibodies (mAb or moAb) Monoclonal antibodies are:  monospecific antibodies that are identical.
Trastuzumab [Genentech Inc.] Labeling Supplement to Include FISH Testing as a Method to Select Patients for Treatment FDA Clinical Review December 5, 2001.
MONOCLONAL ANTIBODIES
White blood cells & the immune system What does it mean to be immune to something? Leucocyte (WBC) Phagocytes (engulf & destroy) = Inflammation Lymphocytes.
Introduction Chili peppers are eaten throughout the world in a variety of dishes, and cuisines Capsaicin, an active component in chili peppers, is responsible.
New Developments in Cancer Treatment Dulcinea Quintana, MD.
Advanced Cancer Topics Journal Review 4/16/2009 AD.
The Effect of Bisphenol A on the Growth of Brest Cancer Cells
FUNCTIONAL GENOMICS REVEAL THAT THE SERINE SYNTHESIS PATHWAY IS ESSENTIAL IN BREAST CANCER Introduction: Tim Butler Spellman Lab.
Introduction The effects of HER2 gene and receptor over- expression on breast cancer. Prognosis and treatment of HER2+ breast cancer. (See figure 1)
Isosteviol derivatives induced apoptosis in Human lung cancer via targeting MEK/MAPK pathway: An in vitro and in vivo study Ahmed M Malki 1,,PhD Stephen.
Quantification and DNA Sequencing of IL-13Rα1 and IL-13Rα2 On Various Cancer Cell Lines Erin Dolac, Department of.
Expressing Surface Proteins to Target Cancer Cells Joe and Bobby.
Acknowledgement of funding Regulator of G-protein signaling 5 blunts cellular viability mediated by a stabilized lysophosphatidic acid analogue (2S-OMPT)
Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.
Abstract Introduction  What is a Herceptin (Trastuzumab) ?  Herceptin (Trastuzumab) is an monoclonal antibody,it is an example of targeted therapy an.
Gene Therapy. Gene Therapy is a technique for correcting defective genes responsible for disease development Gene Therapy is a technique for correcting.
Determining the Effect of Triclosan on the Growth of Cancer Cells Lydia Alf and Winnifred Bryant Ph. D. Department of Biology University of Wisconsin,
MOLECULAR MARKERS OF TRASTUZUMAB RESISTANCE IN HER-2 METASTATIC BREAST CANCER PATIENTS Dr. Mazhar Al-Zoubi University of Pisa - Italy.
Developing medicines for the future and why it is challenging Angela Milne.
Dr. Sheila Singh’s Laboratory Lab overview Operating since August 2007 Located at the Stem Cell & Cancer Research Institute at McMaster Main Campus Research.
Overview of Targeted Therapy Mechanisms November 11, 2011 Targeted Therapies and Biological Therapies SIG.
Prognostic and Predictive Factors: Current Evidence for Individualized Therapy Predictive Molecular Markers: Hormone Receptor Status Presented by Kathleen.
Methods for detecting resistance Goal: To determine whether organism expresses resistances to agents potentially used for therapy Designed to determine.
Effects of metformin and thymoquinone on survival of leukemic cells
FIGURE 21.1 Clonogenic Assay for Adherent Cells. Cells are trypsinized, counted, and diluted as for monolayer dilution cloning (see Protocol 13.1). The.
中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 1 Emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu in Her2/neu-overexpressing.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.
Altogen Biosystems offers the J774A Transfection Reagent among a host of 100+ cell line specific In Vitro Transfection Kits. The J774A Transfection Reagent.
RAS Initiative at the Federally Funded Research and Development Center at Frederick Presented By: Sara S. Hook October 1, 2015.
Products > PC-3 Transfection Reagent (Prostate Cancer Cells) Altogen Biosystems offers the PC-3 Transfection Reagent among a host of 100+ cell line specific.
Altogen Biosystems offers the 786-O Transfection Reagent among a host of 100+ cell line specific In Vitro Transfection Kits. 786-O Transfection Reagent.
Effect of Doxorubicin and Paclitaxel on Adipose-Derived Stem Cells: Can we incorporate chemotherapy into our reconstructive strategies? Materials and MethodsAbstract.
Products > MCF-7 Transfection Reagent (Breast Cancer, HTB-22) Altogen Biosystems offers the MCF-7 Transfection Reagent among a host of 100+ cell line specific.
Products > Transfection Reagent for C6 Cells (Glioma Cells, CCL-107) Altogen Biosystems offers the C6 Transfection Reagent among a host of 100+ cell line.
WP2 Combined effect of charged particles irradiation and anticancer drugs in cultured human tumor cells (Milano and Roma 3, collaboration with CNAO and.
多肽类药物研究的新进展 潘婷婷 多肽药物定义: 通常将含有的氨基酸少于 10 个的肽称为寡肽,超过的就 称为多肽。所以多肽药物可以这样说: 从生物化学本质上说是一种肽,具有 10 个氨基酸以上; 从功能上讲具有药物的功能,能用于疾病的预防、治疗与 诊断。
Products > HCC1937 Transfection Reagent (Breast Carcinoma) Altogen Biosystems offers the HCC1937 Transfection Reagent among a host of 100+ cell line specific.
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer José Baselga, M.D., Ph.D., Javier Cortés, M.D., Sung-Bae Kim, M.D., Seock-Ah Im,
Cancer Summit 2007 Using Time-lapse Microscopy to Learn How Tumor Cells Migrate & Invade.
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > NCI-H1299 Transfection Reagent (Lung Adenocarcinoma)
TOPIC OUTLINE Methods of cultivating animal cells
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > 4T1 Transfection Reagent (Breast Cancer Cells, CRL-2539)
Can Drug Discovery Research be Done At An Undergraduate Institution?
Products > Capan-1 Transfection Reagent (Pancreatic Carcinoma)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > BT-20 Transfection Reagent (Breast Carcinoma Cells)
Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.
Antibody Drug Conjugates Services Antibody-drug conjugates Antibody-drug conjugates (ADCs) are a very important class of highly potent drugs designed as.
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > SK-N-MC Transfection Reagent (Neuroblastoma Cells)
Carlos L. Arteaga, Jeffrey A. Engelman  Cancer Cell 
Myung Jin Son, Kevin Woolard, Do-Hyun Nam, Jeongwu Lee, Howard A. Fine 
Volume 15, Issue 2, Pages (February 2007)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
RESEARCH IN MOLECULAR THERAPI
Products > LNCAP Transfection Reagent (Prostate Carcinoma)
Products > NCI-H358 Transfection Reagent (Bronchioalveolar Cells)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > CLBPEC Transfection Reagent (Neuroblastoma Cells)
(Handling and Evaluation of Breast Cancer Biopsy)
Presentation transcript:

CSULA-COH Cancer Collaborative Cancer Cell Culturing and Cytotoxicity Assays for Anticancer Screening at City of Hope CSULA-COH Cancer Collaborative Presented by: Anthony Martinez

Research: Response and Resistance of cancer cells to therapeutic agents Failure of cancer treatment One main cause: drug resistance by tumor Breast cancer is the most common cancer in women (incurable if metastatic) Her2 is overexpressed in 25-30% of breast cancer and helps the cancer resist conventional treatments (Azambuja, 2007)

Hypothesis Some antibiotics are also anti-cancer drugs Examples Doxyrubicin Clioquinol Immune defense in infectious agents and tumor defense display some similarities Antimicrobial lipids produced naturally in body fluids might exert some anticancer activity

Collaborative Design Dr. Kane’s Lab Dr. Porter’s Lab Discover drugs that overcome resistance in cancer Dr. Porter’s Lab Characterize host-derived lipids with antimicrobial activity Molecular Express, Inc. Develop liposomal formulations of antimicrobial lipids University of Wisconsin

Cell Maintenance and Technique Cell growth and passage Tissue culture medium Antibiotics Trypsin, serum, L-glutamine Cryopreservation and storage Cell Counting Hemocytometer Coulter counter Safety and technique An example of removing Media from a T25 flask Masters, J., Stacey, G. (2007). Changing medium and passaging cell lines. Nature Protocols 2: 2276-2284.

Measuring Cytotoxicity Clonogenic Assay (colony forming assay) Sulforhodamine B (SRB Assay)

Colony Forming Assay Treatment is applied to a sample of cells. The cells are plated in a tissue culture vessel and allowed to grow. The colonies produced are fixed, stained, and counted Cell survival – surviving fraction vs. drug concentration

Before Treatment After Treatment Too many to count Franken N., Rodermond H., Stap J, Haveman J, van Bree C. (2006). Clonogenic assay of cells in vitro. Nature Protocols 1: 2315-2319.

The sulforhodamine B (SRB) Assay SRB binds to protein components of cell SRB is bright-pink aminoxanthene dye and binds basic amino groups – binding is stoichiometric to cell mass Adaptable to 96-well, high throughput screening Dose Response Analysis Vichai, V., Kirtikara, K. (2006). Sulforhadamine B colorimetric assay for cytotoxicity screening. Nature Protocols 1: 1112-1116.

Herceptin Study Herceptin (trastuzumab) – monoclonal antibody Used to treat breast cancers over-expressing Her2/neu receptor Disrupt cell signalling pathway – PI-3-kinase/Akt signal transduction pathway

First Results Cells/ml 6 well plate 2 ml/plate Cells/ml A No Herceptin B Cells/ml No Herceptin .01 M 1 M Figure 1: Effect of anti-HER2 monoclonal antibody herceptin on SK-BR-3 cell proliferation. Cell number was determined on the third, seventh and tenth day using the hemocytometer. (A) 3000 cells/ml per well were seeded on day 0. (B) 10,000 cells/ml per well were seeded. Each count was done in duplicate with the error bars representing +/- SD.

Next Steps Complete training at City of Hope Implement various screening protocols with antimicrobial lipid based liposome preparations privided by Molecular Express, Inc. at CSULA

Acknowledgements Beckman Research Institute of City of Hope and Graduate School of Biological Sciences Dr. Susan Kane Dr. Steven Novak Dr. Tom Lebon Dr. Long Gu Cecile Donahue Students and Staff California State University, Los Angeles Faculty and Staff Dr. Edith Porter Dr. Jamil Momand Dr. Sandra Sharp Dr. Nancy McQueen Annie Mirsoian Ronnie Cheng Dr. Gary Fujii Dr. William Ernst Joan-En Chang Funding NIH grants: 1P20CA118783-01A1 and 1P20CA118775-01A1

References Freshney, R. (2005). Culture of Animal Cells: A Manual of Basic Technique, 5th ed. Hoboken, NJ, John Wiley & Sons. Kane, S. (2006). Cancer therapies targeted to the epidermal growth factor receptor and its family members. Expert Opinion on Therapeutic Patents 2: 147-164. Langdon, S. (2004). Cancer Cell Culture: Methods and Protocols, Totowa, NJ, Humana Press. Masters, J., Stacey, G. (2007). Changing medium and passaging cell lines. Nature Protocols 2: 2276-2284. Vichai, V., Kirtikara, K. (2006). Sulforhadamine B colorimetric assay for cytotoxicity screening. Nature Protocols 1: 1112-1116. Franken N., Rodermond H., Stap J, Haveman J, van Bree C. (2006). Clonogenic assay of cells in vitro. Nature Protocols 1: 2315-2319. Azambuja E., Durbecq V., Rosa D.D., Colozza M., Larsimont D., Piccart-Gebhart M., Cardoso F. (2008). HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. Annals of Oncology 19: 223-232.